Floatz Rating
BB65/100
Confidence
Indicative
Sponsor
STCube, Inc.
Modality
unclassified
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
68High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07656038CT.gov Nelmastobart in Combination With Tas-102 and Bevacizumab in Recurrent/Metastatic Colorectal Cancer | — | Not Yet Recruiting | — | — | — |
NCT07318389CT.gov ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer | — | Not Yet Recruiting | — | — | — |
NCT06882915CT.gov Efficacy and Safety of Trifluridine/Tipiracil (TAS-102) Combined With Bevacizumab and Serplulimab in Patients With Metastatic Colorectal Cancer Undergoing Cytoreductive Surgery: A Single-Arm, Single-Center Clinical Study | — | Not Yet Recruiting | — | — | — |
NCT07483684CT.gov A Clinical Study to Evaluate Injection TQB2102 for the Treatment of Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Progressed After Treatment With Oxaliplatin, Irinotecan and Fluoropyrimidine-Based Drugs | — | Not Yet Recruiting | — | — | — |
NCT07384377CT.gov JSKN003 Versus Physician Choiced Treatment in Patients With HER2-positive and Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-Fu, and Irinotecan | — | Not Yet Recruiting | — | — | — |
NCT07044908CT.gov TQB2922 and TAS-102 Tablets for Injection With or Without Bevacizumab in Chemotherapy-failed RAS/BRAF Wild-type Advanced Colorectal Cancer | — | Recruiting | — | — | — |
NCT06199973CT.gov Injection of SHR-A1811 Versus Physician Choiced Treatment in Patients With Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-fu, and Irinotecan | — | Active Not Recruiting | — | — | — |
NCT06293014CT.gov TAS-102 Combined With Bevacizumab for Second-line Maintenance Treatment of Advanced Colorectal Cancer | — | Recruiting | — | — | — |
NCT06039202CT.gov Phase 2 Study of CA102N Combined With TAS-102 Compared to Bevacizumab Combined With TAS-102 in Subjects With Relapsed and/or Refractory Metastatic Colorectal Cancer | — | Unknown | — | — | — |
NCT06092242CT.gov The Efficacy and Safety of TAS-102(Suyuan) Combined With Bevacizumab as First-line Therapy in Patients With Advanced Colorectal Cancer | — | Not Yet Recruiting | — | — | — |
Show 24 more trialsShow fewer
NCT05854498CT.gov Liposomal Irinotecan With TAS102 and Bevacizumab for Patients With Metastatic Colorectal Cancer | — | Recruiting | — | — | — |
NCT06099314CT.gov Fruquintinib in the Cross-line Treatment of Refractory mCRC | — | Unknown | — | — | — |
NCT05364489CT.gov Efficacy, Safety and Exploratory Clinical Study of Bevacizumab Combined With Oxaliplatin and TAS-102 in First-line Treatment of Advanced Colorectal Cancer | — | Not Yet Recruiting | — | — | — |
NCT05600309CT.gov A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)-China Extension Study | — | Completed | — | — | — |
NCT05343013CT.gov TAS-102 With or Without Celecoxib in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy | — | Recruiting | — | — | — |
NCT05314101CT.gov TAS-102 Combined With Bevacizumab and Tislelizumab Third-line or Above in the Treatment of Liver Metastasis in Colorectal Cancer | — | Unknown | — | — | — |
NCT05004831CT.gov Fruquintinib Combined With TAS-102 in the Treatment of Patients With Advanced Metastatic CRC | — | Unknown | — | — | — |
NCT05064059CT.gov A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007) | — | Completed | — | — | — |
NCT05266820CT.gov Trifluridine/Tipiracil (TAS-102) With or Without Thalidomide for the Treatment of Metastatic Colorectal Cancer | — | Unknown | — | — | — |
NCT04920032CT.gov Study of ctDNA Guided Change in Tx for Refractory Minimal Residual Disease in Colon Adenocarcinomas | — | Recruiting | — | — | — |
NCT04868773CT.gov Study of Cabozantinib Plus TAS102 in mCRC as Salvage Therapy | — | Completed | — | — | — |
NCT04999761CT.gov AB122 Platform Study | — | Recruiting | — | — | — |
NCT06221423CT.gov Fruquintinib Combined With TAS-102 in Refractory Metastatic Colorectal Cancer | — | Unknown | — | — | — |
NCT03909724CT.gov Pulsatile High-dose Sunitinib Versus TAS-102 in Patients With Metastatic Colorectal Carcinoma (mCRC) | — | Unknown | — | — | — |
NCT03974594CT.gov Bioequivalence Study of Trifluridine and Tipiracil Tablets in Colorectal Cancer Patients | — | Completed | — | — | — |
NCT03717038CT.gov Sym004 Versus TAS-102 in Patients With mCRC | — | Withdrawn | — | — | — |
NCT03520946CT.gov RAMucirumab in Combination Wth TAS102 vs. TAS102 Alone in Chemotherapy Refractory Metastatic Colorectal Cancer Patients | — | Completed | — | — | — |
NCT03223779CT.gov Study of TAS-102 Plus Radiation Therapy for the Treatment of the Liver in Patients With Hepatic Metastases From Colorectal Cancer | — | Completed | — | — | — |
NCT02860546CT.gov A Study Evaluating TAS-102 Plus Nivolumab in Patients With MSS CRC | — | Completed | — | — | — |
NCT02654639CT.gov Ph 2 Study of TAS-102 / Bevacizumab Maintenance Therapy Post Induction Chemotherapy in Metastatic Colorectal Cancer | — | Terminated | — | — | — |
NCT02613221CT.gov A Phase I/II Study for the Safety and Efficacy of Panitumumab in Combination With TAS-102 for Patients With Colorectal Cancer | — | Completed | — | — | — |
NCT01955837CT.gov Study of Trifluridine/Tipiracil (TAS-102) in Patients With Metastatic Colorectal Cancer in Asia | — | Completed | — | — | — |
NCT01607957CT.gov Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies | — | Completed | — | — | — |
NCT00936832CT.gov Sunitinib Malate and Combination Chemotherapy as Front-Line Therapy in Treating Patients With Metastatic Rectal Cancer That Cannot Be Removed by Surgery | — | Withdrawn | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Colorectal Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Tas-102 (this asset) | STCube, Inc. | P3 | BB · 65 |
| Desflurane | Peter MacCallum Cancer Centre, Australia | P4 | BBB |
| Marble Dust | James Varani | P2/3 | BB |
| Oxaliplatin | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | P4 | BB |
| Orectalip | Sinphar Pharmaceutical Co., Ltd | P4 | BB |
| Fluorouracilum | UNICANCER | P4 | BB |
| Levofolinic Acid | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | P3 | BB |
| Fentanyl | Mansoura University | P4 | BB |
| Panitumumab | MSPU des 3 Provinces | P3 | BB |
+42 more in the Colorectal Cancer cohort
Other indications for Tas-102
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Hepatocellular Carcinoma | — | P3 | B · 60 |
| Colorectal Neoplasm | — | P3 | B · 59 |
| Rectal Carcinoma | — | P3 | B · 59 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Tas-102 in Colorectal Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/tas-102-colorectal-cancer-18503
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →